AKT1 and cardiac hypertrophy: They concluded that HHP-Exo preferentially targets the heart and improves the therapeutic effect of CDC-Exos on cardiac hypertrophy, and that this therapeutic effect is likely due to miR-148a-mediated inhibition of GP130 and inhibition of the STAT3/ERK1/2/AKT signaling pathway, resulting in improved cardiac function and myocardial hypertrophy [132].